Karpov S M, Morozova M Yu, Muravyov K A, Vyshlova I A, Kantemirova F S
Stavropol State Medical University, Stavropol, Russia.
City Clinical Hospital No. 3, Stavropol, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(3. Vyp. 2):59-62. doi: 10.17116/jnevro202212203259.
To evaluate the effect of Mexidol on the recovery of cognitive functions in patients after ischemic stroke (IS).
We examined 70 patients with acute IS, who were randomized into 2 groups by random sampling; The 1st group consisted of patients who, against the background of the main standard therapy for 14 days, received Mexidol intravenously, 500 mg 1 time per day, followed by oral administration of Mexidol FORTE 250, 750 mg per day for 60 days (40 patients; 28 men, 12 women). Group 2 consisted of 30 patients (21 men, 9 women) who received only standard therapy.
Baseline scores on the MoCA and MMSE scales did not differ between the two groups. Retesting showed that the improvement on these scales was statistically more significant in the 1st group. The analysis of indicators of the evoked potential P300 confirmed a more pronounced positive trend in the 1st group (<0.01).
The use of sequential therapy with Mexidol is accompanied by a more complete recovery of cognitive functions in patients who have undergone IS.
评估美西多芬对缺血性卒中（IS）患者认知功能恢复的影响。
我们检查了70例急性IS患者，通过随机抽样将其随机分为2组；第1组患者在为期14天的主要标准治疗基础上，每天静脉注射1次美西多芬500mg，随后口服美西多芬强力片250mg，每天750mg，持续60天（40例患者；28名男性，12名女性）。第2组由30例患者（21名男性，9名女性）组成，他们仅接受标准治疗。
两组在蒙特利尔认知评估量表（MoCA）和简易精神状态检查表（MMSE）上的基线得分无差异。重新测试表明，第1组在这些量表上的改善在统计学上更显著。对诱发电位P300指标的分析证实，第1组有更明显的积极趋势（<0.01）。
对IS患者采用美西多芬序贯治疗可使其认知功能更完全地恢复。
